A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression

Atypical Depression Clinical Trial

Official title:
A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression

Status Completed

Clinical Trial Summary

This is a Pilot Study to get a first indication whether Duloxetine may be effective for depressed patients with Atypical Features.

Clinical Trial Description

This Open Pilot Study will assess whether Duloxetine is effective for patients with Atypical Features. 20 patients having Major Depressive Disorder with Atypical Features or Dysthymic Disorder will receive Duloxetine in open fashion for 8 weeks. Dose will begin with 20 mg/d and increase to PDR maximal dose of 120 mg/d, if tolerated. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00296699
Study type	Interventional
Source	New York State Psychiatric Institute
Contact
Status	Completed
Phase	Phase 4
Start date	March 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00610506` - Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features	Phase 3
Completed	`NCT00215176` - Modafinil for Atypical Depression	Phase 2/Phase 3
Completed	`NCT00861978` - St. John's Wort Extract LI 160 for the Treatment of Atypical Depression	Phase 3
Completed	`NCT00477854` - Effects of Chromium Picolinate on Food Intake	N/A